Professor Peter J. Barnes, FMedSci, FRS, is Professor of Thoracic Medicine and Head of Airway Disease at the National Heart and Lung Institute and Honorary Consultant Physician at Royal Brompton Hospital, London. He qualified at Cambridge and Oxford Universities was appointed to his present post in 1987. He has published over 1,000 peer-review papers on asthma, COPD and related topics and has edited over 40 books.
He is also amongst the top 50 most highly cited researchers in the world and has been the most highly cited clinical scientist in the UK and the most highly cited respiratory researcher in the world over the last 20 years. He was elected a Fellow of the Royal Society in 2007, the first respiratory researcher for over 150 years. He is currently a member of the Scientific Committee of the WHO/NIH global guidelines on asthma (GINA) and COPD (GOLD). He also serves on the Editorial Board of over 30 journals and is currently an Associate Editor of Chest and respiratory Editor of PLoS Medicine. He has given several prestigious lectures, including the Amberson Lecture at the American Thoracic Society and the Sadoul Lecture at the European Respiratory Society.
His research is focused on cellular and molecular mechanisms of asthma and COPD, understanding and developing therapies and research into biomarkers for these diseases. He is involved in multidisciplinary translational research which integrates basic science with clinical studies, thereby providing novel insights into common airway diseases.
Dr. Boucher has extensive experience in the study of the pathophysiology and therapy of chronic airways diseases, including cystic fibrosis. He is currently a William Rand Kenan Professor of Medicine at the University of North Carolina, the Chief of Pulmonary Medicine, Director of the UNC Cystic Fibrosis/Pulmonary Research and Treatment Center, and Co-Director of the UNC Gene Therapy Center. He has published more than 400 papers on all aspects of pulmonary medicine and cystic fibrosis. In addition, Dr. Boucher was a founder of Inspire Pharmaceuticals, a biotechnology company focused on developing novel nucleotide-based therapies for the treatment of lung disease.
Dr. Boucher is Co-Founder & Chairman of the Board of Parion, a privately held development-stage pharmaceutical company focused on the discovery and development of new treatments for pulmonary indications including cystic fibrosis, COPD, and bronchiectasis. He holds more than 30 patents focused on novel therapies of lung diseases. He received his BA from Yale University and his MD from Columbia University.
David Denning is an infectious diseases clinician with expertise in fungal diseases. He spends about 40% of his time seeing patients, principally with various forms of aspergillosis and other forms of fungal disease and complex infection issues. He trained at Guys Hospital, London and as a young doctor also in London (University College and Northwick Park hospitals), Glasgow and Stanford, California. He has been researching, and caring for patients with aspergillosis since 1985. Currently the National Centre receives over 500 new referrals annually. He has published more than 500 papers and book chapters. He has successfully lead many major international collaborative science, diagnostic and treatment projects and clinical guidelines, with subsequent publication in Nature, the New England Journal of Medicine and the Lancet. He is heavily involved in postgraduate teaching and lectures worldwide. He was instrumental in the establishment of the Mycology Reference Centre in Manchester (2009), which grew out of the Fungal Testing Laboratory he founded in 1991. His work has been cited over 50,000 times (Google scholar H-index 103). He is the Founder of 2 University spinout biotechnology companies – F2G Ltd and Myconostica Ltd. He chairs the Editorial Board of The Aspergillus Website (1998-) (www.aspergillus.org.uk) of which ~1 million pages are read monthly. He leads LIFE (Leading International Fungal Education) (www.LIFE-Worldwide.org) and is President of the Global Action Fund for Fungal Infections (http://www.GAFFI.org). He co-chairs the alternate year Advances Against Aspergillosis meetings.
Dr. Edwards is the Gordon McKay Professor of the Practice of Biomedical Engineering at Harvard University, where his work focuses on the fields of fluid mechanics, interfacial transport phenomena, drug delivery, and aerosol science. His current research is supported by grants from the National Institutes of Health and the Bill and Melinda Gates Foundation, and includes the investigation of the fluid mechanical properties of the lung lining fluid that permit control of expired bioaerosol and mitigation of the spread of inhaled infectious disease, the development of novel antibiotic therapies for tuberculosis, and a new delivery platform for needleless childhood vaccines.
Dr. Edwards has published over 70 papers on the aerosol delivery of macromolecules to the lung and a variety of related subjects. He is a Fellow of the American Institute of Medical and Biological Engineering and a Member of the National Academy of Engineering. Dr. Edwards is a recipient of numerous awards including the Professional Progress Award of the American Institute of Chemical Engineers, and is a three time recipient of the Ebert Prize of the American Pharmaceutical Association.
He is a member of the Advisory Board at the Center for Civilian Biodefense Strategies at the Johns Hopkins University. He is also the founder of Advanced Inhalation Research (AIR) which was acquired by Alkermes, Inc., and Chairman of the Board of the international not-for-profit Medicine in Need (MEND).
Professor Tony Hickey, PhD, is Professor Emeritus of Molecular Pharmaceutics of the School of Pharmacy, and Biomedical Engineering of the School of Medicine, at the University of North Carolina at Chapel Hill. He obtained PhD (1984) and DSc (2003) degrees in pharmaceutical sciences from Aston University, Birmingham, UK, following postdoctoral positions, at the University of Kentucky (1984-1988).
Dr. Hickey is founder, President and CEO of Cirrus Pharmaceuticals, Inc. (since 1997), founder (2001, and formerly CSO, 2002-2007) of Oriel Therapeutics, Inc. (acquired by Sandoz Inc. 2010), past Chair of the Aerosols Expert Committee of the United States Pharmacopeia (2005-2010), current member of the Pharmaceutical Dosage Forms Expert Committee (2010-2015) and Program Director for Innovation and Translation Alliances of the not-for-profit, Medicine in Need (since 2009). Dr. Hickey leads a multidisciplinary research group in the field of pulmonary drug and vaccine delivery.
Dr. Langer is the Kenneth J. Germeshausen Professor of Chemical and Biomedical Engineering at the Massachusetts Institute of Technology. The only active member of all three U.S. National Academies (the National Academy of Sciences, the Institute of Medicine, and the National Academy of Engineering), Dr. Langer is one of 14 Institute Professors at MIT. His career has focused on pioneering work at the interface of biotechnology, drug delivery, and materials science, resulting in over 1000 articles and over 600 issued or pending patents worldwide. His patents have further been licensed or sublicensed to over 200 pharmaceutical, chemical, biotechnology, and medical device companies.
Dr. Langer is a founder of over 20 successful companies, including Momenta, Alnylam, Transform Pharmaceuticals, Pervasis, and Advanced Inhalation Research (AIR). Dr. Langer has additionally served as a member of the United States Food and Drug Administration's SCIENCE Board, the FDA's highest advisory board, from 1995 to 2002, and as its Chairman from 1999 to 2002.
Dr. Langer has received over 160 major awards including the 2006 United States National Medal of Science, the Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, and the 2008 Millennium Prize, the world’s largest technology prize. Dr. Langer received his BS from Cornell University, and his ScD from the MIT, both in Chemical Engineering.
Richard B. Moss, MD, is former chief of the Pediatric Pulmonary and Allergy Divisions, and allergy-immunology and pulmonary fellowship training programs director, at Stanford University. He was educated at Columbia (BA), SUNY Downstate (MD), Northwestern/Children’s Memorial Hospital (pediatrics residency) and Stanford (allergy-immunology, pulmonology fellowships). He was Director of the Cystic Fibrosis Center at Stanford (1991-2009) and site principal investigator for the Cystic Fibrosis Therapeutics Development Network (1999-2009), where he was also inaugural Chair of the Protocol Review Committee. He currently is a member of Stanford’s Child Health Research Institute, serves on the Pediatric Mentoring Program at Stanford, the Executive Committee of Stanford’s NIH clinical research program (Spectrum Child Health) and the Stanford IRB. Dr. Moss has reviewed and consulted for the NIH, CFF, national and international foundations, peer-review journals and biopharmaceutical companies. His research interests include pathogenesis, outcome measures, and treatment of chronic airway diseases of childhood. Recent work has focused on allergic fungal lung disease.
Professor Sanjay Sethi, MD, is Chief, Division of Pulmonary, Critical Care and Sleep Medicine, in the Department of Medicine at the University of Buffalo at the State University of New York (SUNY) where he also completed a fellowship in pulmonary and critical care medicine. He is the Chief of the Division of Pulmonary/Critical Care/Sleep Medicine at the University at Buffalo and the Section Chief for Pulmonary/Critical Care/Sleep Medicine at the Western New York Veterans Administration HealthCare System in Buffalo.
Dr. Sethi completed his internship and residency in internal medicine at Cook County Hospital in Chicago, Illinois and is board certified in internal medicine, pulmonary disease, and critical care medicine. Dr. Sethi’s main research interests include respiratory infections and chronic obstructive pulmonary disease, focused on the specific areas of bacterial infection in COPD, epidemiology and clinical implications of antimicrobial resistance and innate lung defense in COPD. Dr. Sethi’s has co-authored more than a 100 research articles and reviews in many peer-reviewed medical journals including New England Journal of Medicine, American Journal of Respiratory and Critical Care Medicine, Chest, COPD: Journal of Chronic Obstructive Pulmonary Disease, Infection and Immunity, Journal of Infectious Diseases, and Journal of Antimicrobial Chemotherapy.